Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire Grenoble Alpes maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action for this entity. This suggests a streamlined prosecution profile where the organization is currently pursuing a specific set of biological or pharmaceutical claims. The focused nature of the active matters indicates a targeted investment in protecting core research outcomes.
The examination process is overseen by a distinct examiner within 1 distinct art unit. This concentration indicates that the organization's current intellectual property is being evaluated by a specialized unit. ROBERT A WAX is the busiest examiner, currently responsible for the busiest examiner pending office action. This individual is the sole point of contact for the organization's active patent matters at this time, which reduces the complexity of managing examiner relations.
The use of the distinct art unit simplifies the technical arguments required, as the examiner is likely a specialist in the relevant Biotechnology & Pharmaceuticals niche. With 1 pending office action, the prosecution team can dedicate its full attention to the concerns raised by ROBERT A WAX. This focused interaction allows for a precise response strategy without the need to coordinate across multiple examiners or art units, potentially accelerating the path to allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17437361 | COMPOSITION AND ASSOCIATED DELIVERY DEVICE FOR HYDROGEN THERAPY | WAX, ROBERT A | 55d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17437361 | COMPOSITION AND ASSOCIATED DELIVERY DEVICE FOR HYDROGEN THERAPY | WAX, ROBERT A | 1615 | §103 | Final Rejection | 55d | Pending | Sep 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire Grenoble Alpes has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Centre Hospitalier Universitaire Grenoble Alpes's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
